George Elston - May 25, 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
May 25, 2023
Transactions value $
$0
Form type
4
Date filed
5/30/2023, 05:13 PM
Previous filing
Feb 13, 2023
Next filing
Jun 22, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Award $0 +45K $0.00 45K May 25, 2023 Common Stock 45K $5.93 Direct F1
transaction EYPT Restricted Stock Units Award $0 +22.5K $0.00 22.5K May 25, 2023 Common Stock 22.5K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option to purchase will vest and become exercisable as follows: 25% at May 25th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
F2 The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.